Copay help by condition · Cancer and blood cancer · read 2026-11-08
Metastatic Melanoma: which charitable copay funds are open
All 2 funds we hold for Metastatic Melanoma are closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Metastatic Melanoma
- Closed or at capacityMetastatic Melanoma
Good Days ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund's list item on the page carries the class closed). Source page
- Closed or at capacityMetastatic melanoma
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $10,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Metastatic Melanoma
5 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 5 have a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Mektovi Binimetinib Every route for this drug | ... in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) | not in the CMS negotiated-price file |
| Tafinlar Dabrafenib Mesylate Every route for this drug | TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Novartis Patient Assistance Foundation (NPAF) (program page) | not in the CMS negotiated-price file |
| Braftovi Encorafenib Every route for this drug | Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test. Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) | not in the CMS negotiated-price file |
| Keytruda Pembrolizumab Every route for this drug | Melanoma for the treatment of patients with unresectable or metastatic melanoma. Label on openFDA, read 2026-11-10 | Keytruda Assistance (via Merck Helps) Merck Patient Assistance Program Cancer Drug Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Mekinist Trametinib Dimethyl Sulfoxide Every route for this drug | MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Novartis Patient Assistance Foundation (NPAF) (program page) | not in the CMS negotiated-price file |
Funds for costs around Metastatic Melanoma
These pay for a kind of cost, not a diagnosis. Each is shown with its own status.
Funds for costs around cancer and blood cancer in general: behavioral health (1 open of 2), caregiver support (0 open of 2), clinical trial costs (0 open of 1), home care (1 open of 1), named fund (0 open of 1), pain management (0 open of 1), testing (1 open of 1) and transportation (0 open of 1). Every one is listed, with its source, on the Cancer and blood cancer page.
Related conditions
Group: Cancer and blood cancer. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: metastatic-melanoma.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Metastatic Melanoma?
As read on 2026-11-08, none of the 2 funds we hold for Metastatic Melanoma say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Metastatic Melanoma?
Good Days and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.